These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
518 related articles for article (PubMed ID: 33942348)
21. Low-grade mucosa-associated lymphoid tissue lymphoma: a retrospective analysis of 97 patients by the Hellenic Cooperative Oncology Group (HeCOG). Papaxoinis G; Fountzilas G; Rontogianni D; Dimopoulos MA; Pavlidis N; Tsatalas C; Pectasides D; Xiros N; Economopoulos T Ann Oncol; 2008 Apr; 19(4):780-6. PubMed ID: 18156143 [TBL] [Abstract][Full Text] [Related]
22. A phase II study of the PI3K inhibitor copanlisib in combination with the anti-CD20 monoclonal antibody rituximab for patients with marginal zone lymphoma: treatment rationale and protocol design of the COUP-1 trial. Grunenberg A; Kaiser LM; Woelfle S; Schmelzle B; Viardot A; Möller P; Barth TFE; Muche R; Dreyhaupt J; Raderer M; Kiesewetter B; Buske C BMC Cancer; 2021 Jun; 21(1):749. PubMed ID: 34187401 [TBL] [Abstract][Full Text] [Related]
23. Outcomes of bendamustine- or cyclophosphamide-based first-line chemotherapy in older patients with indolent B-cell lymphoma. Olszewski AJ; Butera JN; Reagan JL; Castillo JJ Am J Hematol; 2020 Apr; 95(4):354-361. PubMed ID: 31849108 [TBL] [Abstract][Full Text] [Related]
24. Survival of patients with marginal zone lymphoma: analysis of the Surveillance, Epidemiology, and End Results database. Olszewski AJ; Castillo JJ Cancer; 2013 Feb; 119(3):629-38. PubMed ID: 22893605 [TBL] [Abstract][Full Text] [Related]
28. Similar effectiveness of R-CHOP-14 and -21 in diffuse large B-cell lymphoma-data from the prospective German Tumour Registry Lymphatic Neoplasms. Knauf W; Abenhardt W; Mohm J; Rauh J; Harde J; Kaiser-Osterhues A; Jänicke M; Marschner N; Eur J Haematol; 2019 Nov; 103(5):460-471. PubMed ID: 31314918 [TBL] [Abstract][Full Text] [Related]
29. First-line R-CVP versus R-CHOP induction immunochemotherapy for indolent lymphoma with rituximab maintenance. A multicentre, phase III randomized study by the Polish Lymphoma Research Group PLRG4. Walewski J; Paszkiewicz-Kozik E; Michalski W; Rymkiewicz G; Szpila T; Butrym A; Giza A; Zaucha JM; Kalinka-Warzocha E; Wieczorkiewicz A; Zimowska-Curyło D; Knopińska-Posłuszny W; Tyczyńska A; Romejko-Jarosińska J; Dąbrowska-Iwanicka A; Gruszecka B; Jamrozek-Jedlińska M; Borawska A; Hołda W; Porowska A; Romanowicz A; Hellmann A; Stella-Hołowiecka B; Deptała A; Jurczak W Br J Haematol; 2020 Mar; 188(6):898-906. PubMed ID: 31792945 [TBL] [Abstract][Full Text] [Related]
30. Splenic and nodal marginal zone lymphomas are indolent disorders at high hepatitis C virus seroprevalence with distinct presenting features but similar morphologic and phenotypic profiles. Arcaini L; Paulli M; Boveri E; Vallisa D; Bernuzzi P; Orlandi E; Incardona P; Brusamolino E; Passamonti F; Burcheri S; Schena C; Pascutto C; Cavanna L; Magrini U; Lazzarino M Cancer; 2004 Jan; 100(1):107-15. PubMed ID: 14692030 [TBL] [Abstract][Full Text] [Related]
31. Extranodal Marginal Zone Lymphoma of Mucosa-Associated Lymphoid Tissue of the Salivary Glands: A Multicenter, International Experience of 248 Patients (IELSG 41). Jackson AE; Mian M; Kalpadakis C; Pangalis GA; Stathis A; Porro E; Conconi A; Cortelazzo S; Gaidano G; Lopez Guillermo A; Johnson PW; Martelli M; Martinelli G; Thieblemont C; McPhail ED; Copie-Bergman C; Pileri SA; Jack A; Campo E; Mazzucchelli L; Ristow K; Habermann TM; Cavalli F; Nowakowski GS; Zucca E Oncologist; 2015 Oct; 20(10):1149-53. PubMed ID: 26268740 [TBL] [Abstract][Full Text] [Related]
32. Trends in incidence, therapy and outcome of localized nodal and extranodal marginal zone lymphomas: declining incidence and inferior outcome for gastrointestinal sites. Kuper-Hommel MJ; van de Schans SA; Vreugdenhil G; van Krieken JH; Coebergh JW Leuk Lymphoma; 2013 Sep; 54(9):1891-7. PubMed ID: 23302044 [TBL] [Abstract][Full Text] [Related]
33. Marginal zone lymphoma: old, new, targeted, and epigenetic therapies. Joshi M; Sheikh H; Abbi K; Long S; Sharma K; Tulchinsky M; Epner E Ther Adv Hematol; 2012 Oct; 3(5):275-90. PubMed ID: 23616915 [TBL] [Abstract][Full Text] [Related]
35. Rituximab plus bendamustine is active in pretreated patients with extragastric marginal zone B cell lymphoma of the mucosa-associated lymphoid tissue (MALT lymphoma). Kiesewetter B; Mayerhoefer ME; Lukas J; Zielinski CC; Müllauer L; Raderer M Ann Hematol; 2014 Feb; 93(2):249-53. PubMed ID: 23925930 [TBL] [Abstract][Full Text] [Related]
36. Combination therapy with rituximab and intravenous or oral fludarabine in the first-line, systemic treatment of patients with extranodal marginal zone B-cell lymphoma of the mucosa-associated lymphoid tissue type. Salar A; Domingo-Domenech E; Estany C; Canales MA; Gallardo F; Servitje O; Fraile G; Montalbán C Cancer; 2009 Nov; 115(22):5210-7. PubMed ID: 19672998 [TBL] [Abstract][Full Text] [Related]
37. Non-gastric advanced mucosa-associated lymphoid tissue (MALT) lymphoma has worse prognosis than gastric MALT lymphoma even when treated with rituximab-containing chemotherapy. Ueda K; Terui Y; Yokoyama M; Sakajiri S; Nishimura N; Tsuyama N; Takeuchi K; Hatake K Leuk Lymphoma; 2013 Sep; 54(9):1928-33. PubMed ID: 23216271 [TBL] [Abstract][Full Text] [Related]
38. Delphi consensus recommendations on treatment for advanced-stage marginal zone lymphoma in South Korea. Kim SJ; Yoon SY; Chua S; Byun H; Kim J; Ng J Ann Hematol; 2024 Sep; 103(9):3615-3625. PubMed ID: 39103723 [TBL] [Abstract][Full Text] [Related]
39. An international analysis evaluating frontline bendamustine with rituximab in extranodal marginal zone lymphoma. Alderuccio JP; Arcaini L; Watkins MP; Beaven AW; Shouse G; Epperla N; Spina M; Stefanovic A; Sandoval-Sus J; Torka P; Alpert AB; Olszewski AJ; Kim SH; Hess B; Gaballa S; Ayyappan S; Castillo JJ; Argnani L; Voorhees TJ; Saba R; Chowdhury SM; Vargas F; Reis IM; Kwon D; Alexander JS; Zhao W; Edwards D; Martin P; Cencini E; Kamdar M; Link BK; Logothetis CN; Herrera AF; Friedberg JW; Kahl BS; Luminari S; Zinzani PL; Lossos IS Blood Adv; 2022 Apr; 6(7):2035-2044. PubMed ID: 35196377 [TBL] [Abstract][Full Text] [Related]